Osteoarthritis is a constantly evolving disease. It is a real public health issue. It is therefore important to re-examine the disease and prevent it so that it doesn't affect sufferers' day-to-day lives.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Intra-articular injection of inorganic pyrophosphate improves IL-1β-induced cartilage damage in rat model of knee osteoarthritis in vivo.
Osteoarthr Cartil Open
March 2025
Université de Lorraine, CNRS (French National Centre for Scientific Research), IMoPA (Molecular Engineering and Articular Physiopathology), F-54000, Nancy, France.
Objective: Osteoarthritis (OA) is the most common form of chronic joint disease, affecting mainly the elderly population. This disorder is caused by cartilage degeneration with complex changes in the chondrocyte phenotype. Inorganic pyrophosphate (PPi) was shown to counteract the detrimental effect of interleukin (IL)-1β challenging in an in vitro OA model based on rat articular chondrocytes.
View Article and Find Full Text PDFA comparative analysis of the prevalence and predictors of chronic pain in older adults with and without intellectual disability in Australia.
J Intellect Dev Disabil
March 2024
University of Sydney, Camperdown, Australia.
Background: There is little research comparatively assessing prevalence of pain between older people either with or without intellectual disability. This paper explores health and social factors associated with chronic pain in these two groups.
Method: A cross-sectional survey was undertaken in New South Wales and Queensland, Australia.
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Nat Rev Nephrol
January 2025
APHP, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, and Filière OSCAR, endo ERN and ERN BOND, Paris, France.
X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert.
View Article and Find Full Text PDFExploring musculoskeletal disorders in end-stage kidney disease: a systematic review.
Med J Malaysia
January 2025
International Medical University, Department of Orthopaedics, Kuala Lumpur, Malaysia.
Introduction: This study focuses on the association between musculoskeletal disorders and chronic kidney disease (CKD), specifically end-stage kidney disease (ESKD). Its primary objective is to explore the spectrum of musculoskeletal disorders and to identify their prevalence rates and symptoms within diverse CKD subpopulations.
Materials And Methods: The screening process yielded 13 studies conducted in various countries and regions.
Postnatal deletion of Phlpp1 in chondrocytes delays post-traumatic osteoarthritis in male mice.
Osteoarthr Cartil Open
March 2025
Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
Objective: Osteoarthritis is a chronic, debilitating disease that causes long-term pain and immobility. Germline deletion of Phlpp1 or administration of small molecules that inhibit Phlpp1 prevents post-traumatic osteoarthritis (PTOA) in mice. However, the chondrocyte-intrinsic role of Phlpp1 in PTOA progression is unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!